Novel Prognostic Indicators of Long Noncoding RNA Somatostatin Receptor 5 Antisense RNA 1 and Tubulin Alpha 4B in Prognosis of Nasopharyngeal Carcinoma

Abstract

Long noncoding RNAs are involved in the pathogenesis of nasopharyngeal carcinoma. This study was designed to investigate the clinical roles of long noncoding RNAs somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B in prediction of nasopharyngeal carcinoma prognosis. Reverse transcriptionquantitative polymerase chain reaction was performed to detect gene expression levels. The relationship between aberrant expressions of somatostatin receptor 5 antisense RNA 1, tubulin alpha 4B, 5 y overall survival and relapse-free survival rates were evaluated by Kaplan-Meier analysis. The clinical effects of somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B in nasopharyngeal carcinoma cell viability and apoptosis were further verified and evaluated by the in vitro experiments. We found that expression levels of somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B were significantly decreased in serum of nasopharyngeal carcinoma patients and nasopharyngeal carcinoma cell lines. Somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B expression levels were associated with the node stage, clinical stage and grade of nasopharyngeal carcinoma. In addition, nasopharyngeal carcinoma patients with lower somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B expression presented shorter 5 y overall survival and relapse-free survival rates than those with higher expression. After receiving chemoradiotherapy, the expression levels of somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B were significantly increased. In vitro experimental results further verified that somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B overexpression strongly promote nasopharyngeal carcinoma cell apoptosis. To sum up, tumor-suppressors long noncoding RNAs somatostatin receptor 5 antisense RNA 1 and tubulin alpha 4B might be potential indicators for nasopharyngeal carcinoma prognosis and treatment.